Further, we investigated the expression of immune checkpoints including PD-L1, CTLA4, TIGIT, TIM-3 and LAG-3 between the high-risk and low-risk groups of patients, and the results showed the high-risk patients had higher expression of CTLA4, LAG3 and TIGIT than the low-risk patients indicating the immune targeting potential for this group of ccRCC patients. The gene discussed is TIGIT; the disease is nonpapillary renal cell carcinoma.